Abstract 13946: Sleep Problems on Simvastatin Differentially Predict Weight Change in Men

Background and Goal: Sleep problems were significantly increased on simvastatin ( simva ) (but not pravastatin) vs placebo in the UCSD Statin Study. Sleep problems on simva predicted glucose rise. Weight gain has also been reported as a statin side effect. We sought to capitalize on existing data to assess whether sleep problems on simva related to weight gain in men. Method: 442 men without known diabetes or CVD were randomized to simva 20mg or placebo for 6 mon. One hundred eighty and 186 completed single-item self-rating of change in sleep problems vs baseline ( Δslpprob ). Weight (lb) was measured at baseline and 6 mon. Missing 6 mon values were imputed. Analyses: A. Regressions stratified by treatment assessed prediction of weight change by Δslpprob, adjusted for baseline weight. B. Regressions assessed prediction of weight change by the interaction term of simva (vs placebo) x Δslpprob, adjusted for the components of the interaction and baseline weight. Since age-related muscle loss may complicate weight change in elderly; and young adults have low vulnerability to metabolic problems, analyses were repeated excluding these groups. Results: A. Increased sleep problems on simva predicted weight gain (significant), but on placebo predicted weight loss (nonsignificant). B. The Δslpprob x simva interaction term significantly predicted weight gain. When that was parceled out, simva, outside of the sleep relationship, negatively predicted weight change. Exclusion of young adults and elderly strengthened significance of findings (Table). Discussion: Sleep problems, which differentially arise on simva, differentially predict weight gain on simva. This expands the metabolic effects to which sleep problems on simva may contribute and might possibly favor mediation by sleep apnea (a reported complication of simva). Once the sleep problem effect is considered, simva use predicted weight loss . The relative contribution of fat vs muscle loss (vs other) requires exploration.

Download Full-text

P01-249-Weight change and metabolic effects of asenapine in placebo- or olanzapine-controlled studies

European Psychiatry ◽

10.1016/s0924-9338(11)71960-5 ◽

2011 ◽

Vol 26 (S2) ◽

pp. 250-250

Author(s):

J. Zhao ◽

P. Cazorla ◽

J. Schoemaker ◽

M. Mackle ◽

J. Panagides ◽

...

Keyword(s):

Weight Gain ◽

Weight Change ◽

Serum Lipids ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Metabolic Effects ◽

Glucose Levels ◽

Baseline Weight ◽

Image Position ◽

Post Hoc

IntroductionWeight change and metabolic effects of atypical antipsychotics vary considerably.ObjectiveAssess weight and metabolic effects of asenapine in adults.AimDemonstrate that asenapine marketed doses are well tolerated compared with placebo or olanzapine.MethodsData were from pooled asenapine trials that used placebo (1748 patients; duration: 1−6 wk) and/or olanzapine (3430 patients; duration, 3−>100 wk) controls. Asenapine doses were 5 or 10 mg BID (2–20 mg BID in 2 studies); olanzapine doses were 5–20 mg QD. Post hoc inferential analyses based on ANOVA assessed change from baseline weight, body mass index, and fasting lipid and glucose levels.ResultsTable 1 summarizes the results.[Change From Baseline Weight and Metabolic Paramete]DiscussionThese post hoc pooled analyses support published reports and suggest asenapine was associated with moderate weight gain and increased fasting triglyceride and glucose levels vs placebo, but lower propensity for weight gain or increased serum lipids (ie, triglycerides, low-density lipoprotein, and cholesterol) vs olanzapine.

Download Full-text

Patterns of weight change in a weight gain prevention study for young adults

Obesity ◽

10.1002/oby.23268 ◽

2021 ◽

Author(s):

Jacqueline F. Hayes ◽

Deborah F. Tate ◽

Mark A. Espeland ◽

Jessica Gokee LaRose ◽

Amy A. Gorin ◽

...

Keyword(s):

Young Adults ◽

Weight Gain ◽

Weight Change ◽

Weight Gain Prevention ◽

Prevention Study

Download Full-text

Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: Cohort study in THIN, a UK primary care database

Journal of Psychopharmacology ◽

10.1177/0269881118780011 ◽

2018 ◽

Vol 32 (10) ◽

pp. 1098-1103 ◽

Cited By ~ 3

Author(s):

David PJ Osborn ◽

Irene Petersen ◽

Nick Beckley ◽

Kate Walters ◽

Irwin Nazareth ◽

...

Keyword(s):

Primary Care ◽

Cohort Study ◽

Weight Gain ◽

Confidence Interval ◽

Weight Change ◽

Antipsychotic Treatment ◽

Weight Changes ◽

Baseline Weight ◽

Care Database

Background: Follow-up studies of weight gain related to antipsychotic treatment beyond a year are limited in number. We compared weight change in the three most commonly prescribed antipsychotics in a representative UK General Practice database. Method: We conducted a cohort study in United Kingdom primary care records of people newly prescribed olanzapine, quetiapine or risperidone. The primary outcome was weight in each six month period for two years after treatment initiation. Weight changes were compared using linear regression, adjusted for age, baseline weight and diagnosis. Results: N = 6338 people received olanzapine, 12,984 quetiapine and 6556 risperidone. Baseline weight was lowest for men treated with olanzapine (80.8 kg versus 83.5 kg quetiapine, 82.0 kg risperidone) and women treated with olanzapine (67.7 kg versus 71.5 kg quetiapine 68.4 kg risperidone. Weight gain occurred during treatment with all three drugs. Compared with risperidone mean weight gain was higher with olanzapine (adjusted co-efficient +1.24 kg (95% confidence interval: 0.69–1.79 kg per six months) for men and +0.77 kg (95% confidence interval: 0.29–1.24 kg) for women). Weight gain with quetiapine was lower in unadjusted models compared with risperidone, but this difference was not significant after adjustment. Conclusion: Olanzapine is more commonly prescribed to people with lower weight. However, after accounting for baseline weight, age, sex and diagnosis, olanzapine is still associated with greater weight gain over two years than risperidone or quetiapine. Baseline weight does not ameliorate the risks of weight gain associated with antipsychotic medication. Weight gain should be assertively discussed and managed for people prescribed antipsychotics, especially olanzapine.

Download Full-text

Age-associated changes in hypothalamic–pituitary–testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study

Acta Endocrinologica ◽

10.1530/eje-12-0890 ◽

2013 ◽

Vol 168 (3) ◽

pp. 445-455 ◽

Cited By ~ 187

Author(s):

E M Camacho ◽

I T Huhtaniemi ◽

T W O'Neill ◽

J D Finn ◽

S R Pye ◽

...

Keyword(s):

Weight Loss ◽

Weight Gain ◽

Weight Change ◽

Lifestyle Factors ◽

Community Dwelling ◽

Sex Hormone Binding Globulin ◽

Curvilinear Relationship ◽

Lifestyle Modifications ◽

Age Related ◽

Hpt Axis

ObjectiveHealth and lifestyle factors are associated with variations in serum testosterone levels in ageing men. However, it remains unclear how age-related changes in testosterone may be attenuated by lifestyle modifications. The objective was to investigate the longitudinal relationships between changes in health and lifestyle factors with changes in hormones of the reproductive endocrine axis in ageing men.DesignA longitudinal survey of 2736 community-dwelling men aged 40–79 years at baseline recruited from eight centres across Europe. Follow-up assessment occurred mean (±s.d.) 4.4±0.3 years later.ResultsPaired testosterone results were available for 2395 men. Mean (±s.d.) annualised hormone changes were as follows: testosterone −0.1±0.95 nmol/l; free testosterone (FT) −3.83±16.8 pmol/l; sex hormone-binding globulin (SHBG) 0.56±2.5 nmol/l and LH 0.08±0.57 U/l. Weight loss was associated with a proportional increase, and weight gain a proportional decrease, in testosterone and SHBG. FT showed a curvilinear relationship to weight change; only those who gained or lost ≥15% of weight showed a significant change (in the same direction as testosterone). Smoking cessation was associated with a greater decline in testosterone than being a non-smoker, which was unrelated to weight change. Changes in number of comorbid conditions or physical activity were not associated with significant alterations in hypothalamic–pituitary–testicular (HPT) axis function.ConclusionsBody weight and lifestyle factors influence HPT axis function in ageing. Weight loss was associated with a rise, and weight gain a fall, in testosterone, FT and SHBG. Weight management appears to be important in maintaining circulating testosterone in ageing men, and obesity-associated changes in HPT axis hormones are reversible following weight reduction.

Download Full-text

MMP12 knockout prevents weight and muscle loss in tumor-bearing mice

BMC Cancer ◽

10.1186/s12885-021-09004-y ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Lingbi Jiang ◽

Mingming Yang ◽

Shihui He ◽

Zhengyang Li ◽

Haobin Li ◽

...

Keyword(s):

Colorectal Cancer ◽

Weight Loss ◽

Body Weight ◽

Weight Gain ◽

Tumor Cells ◽

Quantitative Polymerase Chain Reaction ◽

The Body ◽

Muscle Loss ◽

Age Related ◽

Muscle Tissues

Abstract Background Colorectal cancer is a malignant gastrointestinal cancer, in which some advanced patients would develop cancer cachexia (CAC). CAC is defined as a multi-factorial syndrome characterized by weight loss and muscle loss (with or without fat mass), leading to progressive dysfunction, thereby increasing morbidity and mortality. ApcMin/+ mice develop spontaneous intestinal adenoma, which provides an established model of colorectal cancer for CAC study. Upon studying the ApcMin/+ mouse model, we observed a marked decrease in weight gain beginning around week 15. Such a reduction in weight gain was rescued when ApcMin/+ mice were crossed with MMP12−/− mice, indicating that MMP12 has a role in age-related ApcMin/+-associated weight loss. As a control, the weight of MMP12−/− mice on a weekly basis, their weight were not significantly different from those of WT mice. Methods ApcMin/+; MMP12−/− mice were obtained by crossing ApcMin/+ mice with MMP12 knockout (MMP12 −/−) mice. Histological scores were assessed using hematoxylin-eosin (H&E) staining. MMP12 expression was confirmed by immunohistochemistry and immunofluorescence staining. ELISA, protein microarrays and quantitative Polymerase Chain Reaction (qPCR) were used to investigate whether tumor could up-regulate IL-6. Cell-based assays and western blot were used to verify the regulatory relationship between IL-6 and MMP12. Fluorescence intensity was measured to determine whether MMP12 is associated with insulin and insulin-like growth factor 1 (IGF-1) in vitro. MMP12 inhibitors were used to explore whether MMP12 could affect the body weight of ApcMin/+ mice. Results MMP12 knockout led to weight gain and expansion of muscle fiber cross-sectional area (all mice had C57BL/6 background) in ApcMin/+ mice, while inhibiting MMP12 could suppress weight loss in ApcMin/+ mice. MMP12 was up-regulated in muscle tissues and peritoneal macrophages of ApcMin/+ mice. IL-6 in tumor cells and colorectal cancer patients is up-regulation. IL-6 stimulated MMP12 secretion of macrophage. Conclusions MMP12 is essential for controlling body weight of Apc Min/+ mice. Our study shows that it exists the crosstalk between cancer cells and macrophages in muscle tissues that tumor cells secrete IL-6 inducing macrophages to up-regulate MMP12. This study may provide a new perspective of MMP12 in the treatment for weight loss induced by CAC.

Download Full-text

Health-care access and weight change among young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study

Public Health Nutrition ◽

10.1017/s1368980012003813 ◽

2012 ◽

Vol 16 (10) ◽

pp. 1796-1800

Author(s):

Joyce W Tang ◽

Norrina Allen ◽

Peter de Chavez ◽

David C Goff ◽

Catarina I Kiefe ◽

...

Keyword(s):

Health Care ◽

Young Adults ◽

Weight Gain ◽

Health Care Access ◽

Weight Change ◽

Weight Control ◽

Care Access ◽

Control Programmes ◽

Diet Pills ◽

Meal Replacements

AbstractObjectiveHealth-care access is associated with improved control of multiple chronic diseases, but the association between health-care access and weight change is unclear. The present study aims to test the association between health-care access and weight change.DesignThe Coronary Artery Risk Development in Young Adults (CARDIA) Study is a multicentre population-based prospective study. Weight change was calculated at 3 and 13 years after CARDIA year 7 (1992–1993). Health-care access was defined as no barriers or one or more barriers to access (health insurance gap, no usual source of care, not seeking care due to expense). Intermediary variables evaluated included history of dieting and use of diet pills, meal replacements or weight-control programmes.SettingFour cities in the USA.SubjectsParticipants were aged 18–30 years at baseline (1985–1986). Analyses include 3922 black and white men and women with relevant data from CARDIA years 7, 10 and 20 (1992–1993, 1995–1996 and 2005–2006, respectively).ResultsMean weight change was +2·22 kg (+4·9 lb) by 3 years and +8·48 kg (+18·7 lb) by 13 years, with no differences by health-care access. Being on a weight-reducing diet was not consistently associated with health-care access across examinations. Use of diet pills, meal replacements or organized weight-control programmes was low, and did not vary by health-care access.ConclusionsWeight gain was high irrespective of health-care access. Public health and clinical approaches are needed to address weight gain.

Download Full-text

Treatment-Related Weight Change and Overall Survival in United States Veterans with Follicular Lymphoma

Blood ◽

10.1182/blood.v126.23.2088.2088 ◽

2015 ◽

Vol 126 (23) ◽

pp. 2088-2088

Author(s):

Daphne Y Xiao ◽

Katiuscia O'Brian ◽

Suhong Luo ◽

Kenneth R Carson

Keyword(s):

Overall Survival ◽

Weight Loss ◽

Weight Gain ◽

Weight Change ◽

Treatment Initiation ◽

Disease Specific Survival ◽

Baseline Weight ◽

Cox Analysis ◽

Disease Specific

Abstract Introduction Weight loss during chemotherapy has been associated with decreased overall survival (OS) in various solid tumors. While weight loss >10% in the 6 months leading up to diagnosis is a known adverse prognostic factor for non-Hodgkin's lymphoma (one of the B symptoms), the association between weight loss during chemotherapy and survival in follicular lymphoma (FL) patients is not well understood. Few studies have looked at long-term weight change patterns following chemotherapy treatment in this patient population. We investigated short and long-term weight change trends, predictors, and association with OS and disease-specific survival (DSS) in a cohort of FL patients. Methods FL patients diagnosed and treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) +/- rituximab, CVP (cyclophosphamide, vincristine, and prednisone) +/- rituximab, or rituximab monotherapy regimens between 1998 and 2010 were identified in the Veterans Health Administration database. Data on weight 1 year prior to treatment, at time of first treatment (baseline), and up to 5 years after treatment initiation was obtained. Additional data on height, age, stage, race, comorbidities, date of diagnosis, LDH, and B-symptoms was obtained. Body Mass Index (BMI) at diagnosis was categorized according to World Health Organization criteria. Weight change during treatment is calculated as difference between baseline weight and 3 months after start of treatment. Long-term weight change is calculated as difference between baseline weight and 24 months after start of treatment. Logistic regression identified factors associated with long-term weight gain. Landmark Cox analysis evaluated prognostic significance of weight loss during treatment among patients who survived at least 6 months after treatment initiation. Results 1022 patients met inclusion criteria out of 2235. Mean and median age at diagnosis was 63.6 and 63.0 years respectively, 95.9% were men, and 72.7% had Stage III/IV disease. The mean Charlson co-morbidity score was 2.3. B symptoms were present in 37.9% and LDH was elevated in 26.8%. Mean and median weight change during treatment was -1.4kg (-1.5%) and -0.4kg (-0.6%), with a majority of patients losing weight (56%) and 23% of patients losing >5% of their baseline weight. In contrast, mean and median weight change at 24 months after treatment initiation was +1.2kg (+1.6%) and +1.3kg (+1.6%), with a majority of patients (57%) gaining weight and 14% of patients gaining >10% of their baseline weight after treatment completion. Logistic regression analysis identified factors associated with increased risk of weight gain >10% at 24 months after treatment initiation. These included: weight loss >5% in the year prior to treatment (Odds Ratio (OR) 6.82, 95% Confidence Interval (CI) 3.09-15.05), weight gain between 0-5% during treatment (OR 2.53, 95% CI 1.21-5.27), and weight gain >5% during treatment (OR 9.43, 95% CI 3.85-23.14). Kaplan-Meier survival analysis showed that weight loss >5% during treatment was associated with decreased OS (p<0.0001) and disease specific survival (DSS) (p=0.0027) compared to weight loss <5% or weight gain. A landmark Cox analysis controlling for age, disease stage, comorbidities, elevated LDH, B symptoms, BMI at diagnosis, and treatment type showed that weight loss >5% during treatment was independently associated with worse OS (Hazard Ratio (HR) 1.71, 95% CI 1.32-2.22) and DSS (HR 1.61, 95% CI 1.11-2.34). Conclusions In patients with FL, weight loss >5% during treatment is independently predictive of worse overall survival and disease-specific survival. Weight loss could be considered in conjunction with other dynamic variables (such as PET positivity and nodal size) to assess prognosis at the end of therapy. 14% of patients experience long-term weight gain >10% of baseline. Patients who gained 5% or more during treatment are at highest risk (OR=9.4) for long-term weight gain-this subset of patients could be targeted for weight loss interventions to prevent future obesity-related comorbidities. Disclosures No relevant conflicts of interest to declare.

Download Full-text